VX-445/Tezacaftor/Ivacaftor and Ivacaftor

Active substance	VX-445/Tezacaftor/Ivacaftor and Ivacaftor
Holder	Vertex Pharmaceuticals Incorporated
Status	Closed
Indication	Cystic fibrosis (CF) patients in critical need who are 12 years of age and older, homozygous for F508del (F/F genotypes).
Public documents	Approbation Approbation amendment Approbation amendment 2
	Information for the patient Information for the patient amendment Information for the patient amendment 2
	Informed consent Informed consent amendment Informed consent amendment 2
Last update	09/08/2022